GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 275 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $21,582.00. Following the completion of the transaction, the chief financial officer now directly owns 2,950 shares in the company, valued at approximately $231,516. The trade was a 8.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Kevin Feeley also recently made the following trade(s):
- On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
- On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.
- On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $286,124.00.
- On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69.
- On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
- On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.
GeneDx Trading Up 2.9 %
Shares of NASDAQ WGS traded up $2.04 during midday trading on Tuesday, reaching $72.02. The company had a trading volume of 1,077,681 shares, compared to its average volume of 870,931. The stock has a market cap of $1.98 billion, a PE ratio of -23.16 and a beta of 2.01. GeneDx Holdings Corp. has a one year low of $3.63 and a one year high of $98.87. The firm's fifty day moving average price is $77.91 and its 200-day moving average price is $58.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.
Analyst Ratings Changes
A number of equities research analysts have weighed in on WGS shares. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. The Goldman Sachs Group upped their target price on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company lifted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, GeneDx currently has a consensus rating of "Moderate Buy" and an average target price of $70.67.
View Our Latest Research Report on WGS
Institutional Trading of GeneDx
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Fred Alger Management LLC purchased a new stake in shares of GeneDx during the third quarter worth about $16,731,000. Geode Capital Management LLC raised its position in GeneDx by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after purchasing an additional 30,379 shares during the last quarter. State Street Corp lifted its holdings in GeneDx by 18.3% in the 3rd quarter. State Street Corp now owns 314,914 shares of the company's stock worth $13,365,000 after buying an additional 48,735 shares during the period. Millennium Management LLC grew its position in shares of GeneDx by 193.5% in the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company's stock worth $8,140,000 after buying an additional 205,318 shares during the last quarter. Finally, Zweig DiMenna Associates LLC purchased a new position in shares of GeneDx during the fourth quarter valued at approximately $23,788,000. Institutional investors own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Further Reading
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
